Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCKET-ASCEND maintenance study of rocatinlimab for moderate-to-severe atopic dermatitis
CTR20233073Phase 3Terminated
- Sponsor
- Amgen
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of rocatinlimab in atopic dermatitis (AD), sponsored by Amgen. Started Oct 2023; status: terminated.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20233073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233073.